Compartilhar
Informação da revista
Vol. 46. Núm. S4.
HEMO 2024
Páginas S363 (outubro 2024)
Vol. 46. Núm. S4.
HEMO 2024
Páginas S363 (outubro 2024)
Acesso de texto completo
TOWARD OPTIMIZED TREATMENT: INCIDENCE OF HYPERSENSITIVITY REACTIONS AND INACTIVATIONS IN BRAZILIAN CHILDREN RECEIVING PEG-ASPARAGINASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA
Visitas
369
KAS Silvaa,b,c, DK Cecconelloa,b, ECM Sennad, LA Carlottoa, LM Cristofanie, LBP Moreiraf, MLLC Britog, C Rechenmacherb, LE Daudta,b, MB Michalowskia,b
a Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
b Laboratório de Pediatria Translacional, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil
c Hospital da Criança Conceição, Porto Alegre, Brazil
d Universidade de São Paulo (USP), São Paulo, Brazil
e Instituto de Tratamento do Câncer Infantil (ITACI), Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil
f Fundação Doutor Amaral Carvalho, Jaú, Brazil
g Hospital Erasto Gaertner (HEG), Curitiba, PR, Brazil
Este item recebeu
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S4

HEMO 2024

Mais dados
Introduction

PEG asparaginase (PEG-ASNase) is an essential drug in the treatment of acute lymphoblastic leukemia (ALL). However, asparaginase-related hypersensitivity and silent inactivation continue to represent clinical challenges.

Objective

Describe the incidence of hypersensitivity reactions and inactivations associated with PEG-ASNase in Brazilian children undergoing first-line treatment for ALL.

Material and methods

Prospective, multicenter and randomized trial. Patients younger than 18 years with ALL who received PEG-ASNase between February 2021 and February 2024 in eigth differents hospitals were included. ASNase activity was monitored in all patients 7 days and 14 days after each PEG-ASNase.

Results

305 patients were included. 33 (10.8%) patients had clinical allergic reactions and 43 (14.1%) patients had inactivation (asparaginase activity < 0.1 IU/mL). Among those who had allergic reactions, 45.5% also inactivated the drug. There was a significant association between clinical allergic reaction and inactivation (p < 0.001). However, among those who inactivated, 65% did not have an allergic reaction. The silent inactivation rate was 9.2% (n = 28).

Conclusions

Our findings are consistent with the literature, underscoring the importance of therapeutic monitoring of asparaginase for all patients. We aim to further contribute to the treatment of children with ALL by investigating the influence of pre-medication on inactivation and hypersensitivity reactions.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas